Top 100 Contractors in PSC 6505: Drugs and Biologicals, FY2021
Parent companies by net contract obligations Oct 1, 2020 – Sep 30, 2021 Code page on GovTribe
The top 10 won 96% of FY2021 PSC 6505 contract dollars
Ranking facts
- Contract obligations
- $54,731,983,817 Net of deobligations, by contracts coded PSC 6505
- Contractors
- 553 Parent companies with an obligation
- Largest contractor
- Pfizer Inc. $23.1 billion, 41.8% of obligations
- Data as of
Contract actions from FPDS (SAM.gov). How the rankings work · Download all 100 rows as CSV
Full ranking
| Rank | Contractor | Net obligations | Share | Trend |
|---|---|---|---|---|
| 1 | $23,135,431,230 | |||
| 2 | $11,691,182,664 | |||
| 3 |
Modernatx Inc.
Top agencies
|
$6,920,591,679 | ||
| 4 | $5,565,148,165 | |||
| 5 | $1,931,006,454 | |||
| 6 |
ELI Lilly and Company
Top agencies
|
$1,913,730,016 | ||
| 7 |
Merck & Co. Inc.
Top agencies
|
$1,208,123,338 | ||
| 8 |
Glaxosmithkline LLC
|
$317,783,623 | ||
| 9 |
Astrazeneca PLC
|
$287,149,933 | ||
| 10 | $231,561,221 | |||
| 11 | $194,895,927 | |||
| 12 |
Rhino Health, Inc.
Top agencies
|
$126,000,000 | ||
| 13 | $95,497,600 | |||
| 14 | $89,085,333 | |||
| 15 | $69,300,000 | |||
| 16 | $69,176,881 | |||
| 17 | $63,612,248 | |||
| 18 | $53,519,022 | |||
| 19 | $49,996,340 | |||
| 20 | $49,630,288 | |||
| 21 | $45,217,239 | |||
| 22 |
Teva Pharmaceutical Industries Ltd.
Top agencies
|
$39,904,187 | ||
| 23 | $39,418,684 | |||
| 24 | $38,961,000 | |||
| 25 | $34,953,404 | |||
| 26 | $31,618,151 | |||
| 27 | $25,640,549 | |||
| 28 |
Government of Canada
Top agencies
|
$22,972,183 | ||
| 29 | $22,501,800 | |||
| 30 | $21,000,000 | |||
| 31 | $17,453,470 | |||
| 32 |
Boehringer Ingelheim Corporation
Top agencies
|
$16,944,050 | ||
| 33 | $15,295,475 | |||
| 34 | $14,611,967 | |||
| 35 | $12,506,222 | |||
| 36 | $11,000,000 | |||
| 37 |
Johnson & Johnson
|
$9,990,164 | ||
| 38 | $8,845,848 | |||
| 39 |
Mylan Pharmaceuticals Inc.
Top agencies
|
$8,250,000 | ||
| 40 |
Dakco Distributors Inc.
Top agencies
|
$8,056,121 | ||
| 41 | $7,902,695 | |||
| 42 | $7,860,287 | |||
| 43 | $6,932,000 | |||
| 44 |
Catalent Indiana LLC
Top agencies
|
$6,640,000 | ||
| 45 | $6,551,557 | |||
| 46 | $6,215,158 | |||
| 47 | $5,920,615 | |||
| 48 | $5,829,053 | |||
| 49 |
Melling LLC
Top agencies
|
$5,501,584 | ||
| 50 | $5,347,543 | |||
| 51 |
Accredo Health Group Inc.
|
$5,243,442 | ||
| 52 | $4,634,483 | |||
| 53 |
Kaleo, Inc.
Top agencies
|
$4,500,000 | ||
| 54 | $4,337,022 | |||
| 55 | $4,235,690 | |||
| 56 | $4,216,811 | |||
| 57 | $4,190,965 | |||
| 58 | $4,130,740 | |||
| 59 |
Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
|
$3,381,566 | ||
| 60 | $3,367,526 | |||
| 61 |
Biogenesis Bago S.A.
Top agencies
|
$3,162,500 | ||
| 62 | $3,025,955 | |||
| 63 | $3,016,332 | |||
| 64 |
Fresenius Kabi LLC
|
$2,989,712 | ||
| 65 | $2,968,536 | |||
| 66 | $2,821,734 | |||
| 67 | $2,694,334 | |||
| 68 |
Baxter International Inc.
|
$2,549,569 | ||
| 69 |
Henry Schein, Inc.
Top agencies
|
$2,524,698 | ||
| 70 |
Akorn, Inc.
Top agencies
|
$2,400,193 | ||
| 71 | $2,382,048 | |||
| 72 | $2,367,527 | |||
| 73 | $2,351,012 | |||
| 74 |
Roche Holding AG
|
$2,339,657 | ||
| 75 |
Avkare LLC
|
$2,204,214 | ||
| 76 | $2,057,054 | |||
| 77 |
Grifols Diagnostic Solutions Inc.
|
$1,886,155 | ||
| 78 |
Avista Pharma Solutions Inc.
Top agencies
|
$1,837,747 | ||
| 79 |
Bracco SPA
|
$1,801,677 | ||
| 80 | $1,759,020 | |||
| 81 |
Stratatech Corporation
|
$1,721,425 | ||
| 82 | $1,584,974 | |||
| 83 |
Miltenyi Biotec, Inc.
Top agencies
|
$1,493,784 | ||
| 84 | $1,427,178 | |||
| 85 | $1,389,715 | |||
| 86 |
RLS (USA) Inc.
Top agencies
|
$1,372,634 | ||
| 87 | $1,362,530 | |||
| 88 | $1,334,790 | |||
| 89 | $1,255,904 | |||
| 90 |
Sirtex Medical Inc.
|
$1,209,463 | ||
| 91 |
Cambridge Isotope Laboratories Inc.
Top agencies
|
$1,195,823 | ||
| 92 | $1,164,685 | |||
| 93 | $1,151,828 | |||
| 94 | $1,150,461 | |||
| 95 | $1,138,200 | |||
| 96 | $1,102,908 | |||
| 97 | $1,093,131 | |||
| 98 | $1,091,944 | |||
| 99 |
Baxalta US Inc.
|
$1,060,984 | ||
| 100 | $1,000,000 |
Show 75 more
100 of 553 contractors listed here. See the rest on GovTribe.
How this ranking works
- Source: every contract action FPDS records (as published on SAM.gov) in the period, as GovTribe received it.
- Amounts are net obligations: what was obligated, less what was deobligated. Shares are of $55.3 billion obligated before deobligations, so they never pass 100%.
- Parent companies: each action counts under the ultimate parent its award record names, or under the awardee when it names none, so no dollar counts twice. Parents of the same name (Inc., LLC and the like aside) count as one company, since FPDS records a company's parent under more than one UEI over time. GovTribe corrects a few parents and names by hand; see the corrections.
- Fiscal year 2021 ran Oct 1, 2020 – Sep 30, 2021. The Department of Defense reports its contract actions to FPDS about 90 days late, so a fiscal year is ranked once they're in, in February, and the list doesn't change after.
- Rank changes compare with FY2020. "New" marks a company outside that period's top 500, and "Returned" one of those that was on an earlier fiscal year's list.
- Rank lines show each company's rank on every fiscal year's list since FY2021, #1 at the top, on a scale that gives the top of the list more room. A dashed stretch spans years it wasn't on the list. The step from FY2020 takes the color of the rank change beside it.
- Placeholder recipients FPDS uses when it names no company ("Miscellaneous Foreign Contractors" and the like) aren't ranked.
Quick answers
Who were the top 10 PSC 6505 contractors in FY2021?
1. Pfizer Inc. ($23.1B), 2. Mckesson Corporation ($11.7B), 3. Modernatx Inc. ($6.92B), 4. Regeneron Pharmaceuticals Inc. ($5.57B), 5. Cencora, Inc. ($1.93B), 6. ELI Lilly and Company ($1.91B), 7. Merck & Co. Inc. ($1.21B), 8. Glaxosmithkline LLC ($318M), 9. Astrazeneca PLC ($287M), 10. DMS Pharmaceutical Group Inc. ($232M).
On GovTribe
Research every contractor on this list
- Every contract, task order and IDV they hold
- Their subsidiaries, teammates and competitors
- Open opportunities they're positioned for
- Alerts when they win new work